Morgan Stanley’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-7,427
| Closed | -$19.8K | – | 8077 |
|
|
2024
Q1 | $19.8K | Sell |
7,427
-4,013
| -35% | -$9.94K | ﹤0.01% | 6496 |
|
|
2023
Q4 | $27.1K | Sell |
11,440
-11,698
| -51% | -$20.7K | ﹤0.01% | 6553 |
|
|
2023
Q3 | $32.4K | Sell |
23,138
-68,163
| -75% | -$164K | ﹤0.01% | 6329 |
|
|
2023
Q2 | $277K | Buy |
91,301
+50,677
| +125% | +$195K | ﹤0.01% | 5498 |
|
|
2023
Q1 | $254K | Buy |
40,624
+18,102
| +80% | +$110K | ﹤0.01% | 5597 |
|
|
2022
Q4 | $137K | Sell |
22,522
-20,790
| -48% | -$169K | ﹤0.01% | 5830 |
|
|
2022
Q3 | $518K | Sell |
43,312
-11,626
| -21% | -$152K | ﹤0.01% | 5253 |
|
|
2022
Q2 | $693K | Buy |
54,938
+16,247
| +42% | +$151K | ﹤0.01% | 5247 |
|
|
2022
Q1 | $434K | Buy |
38,691
+3,097
| +9% | +$34.1K | ﹤0.01% | 5499 |
|
|
2021
Q4 | $631K | Sell |
35,594
-367,281
| -91% | -$7.75M | ﹤0.01% | 5405 |
|
|
2021
Q3 | $9.27M | Buy |
402,875
+315,822
| +363% | +$6.88M | ﹤0.01% | 2980 |
|
|
2021
Q2 | $2.03M | Buy |
+87,053
| New | +$2.21M | ﹤0.01% | 4622 |
|
Morgan Stanley's KNTE Position: Q2 2024 in Review
Morgan Stanley sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 7,427 shares — an estimated $19.8K sold.
Morgan Stanley first reported a position in KNTE in Q2 2021 and held it in 12 quarters. The position peaked at $9.27M in Q3 2021. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- Morgan Stanley reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Morgan Stanley sold 7,427 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $19.8K.
- Morgan Stanley first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2021 and held it in 12 quarters.
- Morgan Stanley's Kinnate Biopharma Inc. Common Stock position peaked at $9.27M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.